France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the ADC ...

The AAM’s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics ...

Nabla Bio has entered a new multi-year research collaboration with Takeda to advance the AI-driven design of protein ...

Tubulis has completed a Series C, securing €308m ($361m) to be directed towards advancing clinical development of its ADC ...

EMD Serono agreed to provide direct-to-consumer (DTC) sales of its entire range of IVF therapies, including Ovidrel ...

Novo Nordisk will now run a Phase III trial for Omeros' former lead asset, zaltenibart in rare blood disorder, PNH.

With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...

"Meanwhile, Goldman Sachs led by value but faced close competition from JP Morgan. The investment banks had their own notable ...

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...

AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to meet ...

A consortium led by Nordic Capital and Permira has raised its bid, though certain shareholder stances remain firm.

Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).